Abstract |
We assessed the changes in cardiovascular function in humans caused by RO 13-6438, a new drug that enhances cardiac performance, by means of noninvasive methods which included measurement of systolic time intervals and electrical impedance cardiography. Twelve healthy male volunteers received RO 13-6438 doses of 10 and 20 mg intravenously and 20, 40, and 60 mg orally according to a double blind, randomized, crossover, placebo-controlled design. A dose-dependent distinct enhancement in cardiac performance was seen. This was attributed to positive inotropism (shortening of heart rate-corrected electromechanical systole) and to a vasodilating action (decline of diastolic blood pressure and total peripheral resistance). In addition, the drug increased heart rate slightly. The cardiac effects were detectable for 6 h. To reach the average equivalent inotropic response over 6 h, the oral dose was approximately 1.8-fold of the i.v.; this indicated a high bioavailability of RO 13-6438. Transient color vision disturbances were reported mainly following the intravenous administration. The properties of RO 13-6438 suggests that it may be useful for treatment of heart failure.
|
Authors | G G Belz, H C Stern, R Butzer |
Journal | Journal of cardiovascular pharmacology
(J Cardiovasc Pharmacol)
1985 Jan-Feb
Vol. 7
Issue 1
Pg. 86-90
ISSN: 0160-2446 [Print] United States |
PMID | 2580156
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Cardiotonic Agents
- Quinazolines
- Vasodilator Agents
- quazinone
|
Topics |
- Adult
- Blood Pressure
(drug effects)
- Cardiac Output
(drug effects)
- Cardiotonic Agents
(pharmacology, toxicity)
- Dose-Response Relationship, Drug
- Heart Rate
(drug effects)
- Humans
- Male
- Quinazolines
(pharmacology, toxicity)
- Systole
(drug effects)
- Vascular Resistance
(drug effects)
- Vasodilator Agents
(pharmacology, toxicity)
|